1-Oxaspiro<4.5>dec-7-ene | 87151-63-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧唑烯
• 英文名称: 1-Oxaspiro<4.5>dec-7-ene
• 英文别名: (+/-)-1-oxaspiro[4,5]dec-7-ene；1-oxaspiro[4.5]dec-7-ene；1-Oxa-spiro[4.5]dec-7-ene
• CAS: 87151-63-1
• 化学式: C₉H₁₄O
• 分子量: 138.21
• InChiKey: NJNWTZBTAYSXRE-UHFFFAOYSA-N

物化性质

• 沸点：
  50-55 °C(Press: 5 Torr)
• 密度：
  0.98±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2932999099

反应信息

• 作为反应物：
  描述：

  1-Oxaspiro<4.5>dec-7-ene 生成 dihydro-3'H-7-oxaspiro[bicyclo[4.1.0]heptane-3,2'-furan]
  参考文献：
  名称：

  Analgesic 1-oxa-, aza- and thia-spirocyclic compounds

  摘要：

  本发明涉及一类单氧-、硫杂-和螺环苯乙酰胺和苯甲酰胺化合物，其化学式为##STR1##其中p、n、m、A、E、R、R.sub.1、R.sub.2、X、Y和Z如说明书中所定义，例如(.+-.)-(5.alpha.，7.alpha.，9.beta.)-3,4-二氯-N-甲基-N-[7-(1-吡咯烷基)-1-氧杂螺[4.5]癸-8-基]苯乙酰胺及其药学上可接受的盐，作为镇痛化合物具有低的身体依赖性，相比吗啡和美沙酮，以及低的情绪低落副作用。这些化合物中的一些在口服给药时具有强效的镇痛活性，而一些则具有低的中枢神经系统镇静副作用。本发明还公开了将这些化合物作为镇痛剂的制药组合物和方法。本发明还公开了制备这类化合物的方法。

  公开号：

  US04438130A1
• 作为产物：
  描述：

  原白头翁素 在 吡啶 、 锂硼氢 、 对苯二酚 、 对甲苯磺酰氯 、 红铝 、 copper(I) bromide 、 正丁醇 作用下， 以 四氢呋喃 为溶剂， 反应 45.25h， 生成 1-Oxaspiro<4.5>dec-7-ene
  参考文献：
  名称：

  General synthesis of 1-oxaspiro[4.5]decan-2-ones and 1-oxaspiro[4.5]decanes from 5-methylene-2(5H)-furanone

  摘要：

  5-Methylene-2(5H)-furanone underwent Diels-Alder cycloadditions to butadiene and several acyclic and cyclic C-substituted dienes, respectively, affording bicyclic and tricyclic spiroadducts in good yields. These compounds are precursors of other unsaturated and saturated spirolactones and also spiroethers, which were obtained through simple chemical reactions, i.e., hydrogenation of C-C double bonds, reduction of the carbonyl group, and Michael addition. The synthesis of 32 spirolactones and eight spiroethers illustrates the scope and efficiency of this method. Many of these products are suitable for use as components of perfumes and aromas owing to their olfactive properties.

  DOI：

  10.1021/jo00019a019

文献信息

• [EN] CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2<br/>[FR] ANTAGONISTES DU CCR2 À BASE DE CYCLOHEXYL-AZÉTIDINYLE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2011159854A1

  公开（公告）日：2011-12-22

  The present invention comprises compounds of Formula (I). Wherein: R1, R2, R4, J, Q, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

  本发明包括公式(I)的化合物。其中：R1、R2、R4、J、Q和A如说明书所述定义。本发明还包括预防、治疗或改善综合征、障碍或疾病的方法，其中所述综合征、障碍或疾病为2型糖尿病、肥胖和哮喘。本发明还包括通过管理治疗有效量的至少一种公式(I)化合物来抑制哺乳动物中的CCR2活性的方法。
• [EN] NOVEL GLP-1 RECEPTOR MODULATORS<br/>[FR] NOUVEAUX MODULATEURS DU RÉCEPTEUR GLP-1
  申请人：RECEPTOS INC

  公开号：WO2016015014A1

  公开（公告）日：2016-01-28

  Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36), GLP-1(9-36), and oxyntomodulin, or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where "〰" represents either or both the R and S form of the compound): where A, B, C, R1, R2, R3, R4, R5, n, p and q are as defined herein.

  提供了一些化合物，这些化合物可以调节胰高血糖素样肽1（GLP-1）受体，以及它们的合成方法，以及它们的治疗和/或预防使用方法。这类化合物可以单独作为GLP-1受体的调节剂或增强剂，或者与肠促胰岛素肽（如GLP-1(7-36)、GLP-1(9-36)和oxyntomodulin）一起使用，或者与基于肽的治疗方法（如exenatide和liraglutide）一起使用，并且具有以下一般结构（其中"〰"代表化合物R和S形式的任一种或两种）：其中A、B、C、R1、R2、R3、R4、R5、n、p和q如本文所述定义。
• A Practical Synthesis of the Kappa Opioid Receptor Selective Agonist (+)-5<b><i>R</i></b>,7<b><i>S</i></b>,8<b><i>S</i></b>-<b><i>N</i></b>-Methyl-<b><i>N</i></b>-[7-(1-pyrrolidinyl)-1-oxospiro[4,5]dec-8-yl]ben­zeneacetamide (U69,593)
  作者：F. Carroll、Timothy McElroy、James Thomas、George Brine、Hernán Navarro、Jeffrey Deschamps

  DOI：10.1055/s-2008-1032185

  日期：2008.3

  A novel approach to the synthesis of the kappa opioid receptor agonist U69,593 has been developed. This approach improves upon current literature methods by substituting stable and isolable cyclic sulfates for the unstable epoxides. The new approach provides access to gram quantities of the target compound and displays excellent control of the relative stereochemistry. The absolute stereochemistry as well as biological activity of the U69,593 produced by this new method was verified using X-ray crystal structure analysis and binding assays for the kappa opioid receptor.

  一种新颖的合成κ阿片受体激动剂U69,593的方法已被开发出来。该方法通过用稳定且可分离的环状硫酸盐替代不稳定的环氧化物，改善了目前文献中的合成方法。这种新方法能够获取克级的目标化合物，并在相对立体化学方面表现出优异的控制能力。使用X射线晶体结构分析和κ阿片受体结合实验验证了这种新方法合成的U69,593的绝对立体化学及其生物活性。
• Amine intermediates for analgesic compounds
  申请人：The Upjohn Company

  公开号：US04508911A1

  公开（公告）日：1985-04-02

  1,2-Cycloaliphatic diamines and protected diamines of the formulas II and IIa ##STR1## and ##STR2## wherein the wavy line bonds, p, n, R, R.sub.1, R.sub.2, Z, m and Q are as defined in the specification, e.g., (.+-.)-(5.xi.,6.alpha.,7.beta.)-1-[6-methylamino-1-oxaspiro[4.5]dec-7-yl]p yrrolidine, are disclosed and claimed herein. These diamines and protected diamines are useful as intermediates for preparing mono-oxa, and thiaspirocyclic-benzene acetamide and benzamide analgesic compounds.

  本文公开了和声明了二元环脂族二胺和保护二胺的公式II和IIa，其中波浪线键，p，n，R，R.sub.1，R.sub.2，Z，m和Q如规范中所定义，例如(.+-.)-(5.xi.，6.alpha.，7.beta.)-1-[6-甲基氨基-1-氧杂螺[4.5]癸-7-基]吡咯烷。这些二胺和保护二胺可用作制备单氧杂和硫杂螺环苯乙酰胺和苯甲酰胺镇痛化合物的中间体。
• Aminocyclohexanes as Dipeptidyl Peptidase-Iv Inhibitors for the Treatment or Prevention of Diabetes
  申请人：Biftu Tesfaye

  公开号：US20070254865A1

  公开（公告）日：2007-11-01

  The present invention is directed to novel substituted aminocyclohexanes which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DPP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及新型的取代氨基环己烷，其为二肽基肽酶-IV酶（“DPP-IV抑制剂”）的抑制剂，并且对于二肽基肽酶-IV酶参与的疾病，例如糖尿病和特别是2型糖尿病的治疗或预防有用。该发明还涉及包含这些化合物的制药组合物以及在预防或治疗二肽基肽酶-IV酶参与的这些疾病中使用这些化合物和组合物。